Market research
XOMA XOMA Corp
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 710M
- P/E ratio
- 25.59
- Analyst target
- 39
- Dividend yield
- Not available
- Beta
- 0.86
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US98419J2069
- Market cap
- 710M
- P/E ratio
- 25.59
- Analyst target
- 39
- Dividend yield
- Not available
- Beta
- 0.86
About
About XOMA Corp
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets and commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California. As of July 14, 2026, XOMA Royalty Corporation operates as a subsidiary of Ligand Pharmaceuticals Incorporated.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the XOMA discussion.
5 years, 4 months ago
XOMA Corporation is currently in a long term uptrend where the price is trading 1.6% above its 200 day moving average.
From a valuation standpoint, the stock is 98.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 15.9.
XOMA Corporation's total revenue rose by 6435.5% to $28M since the same quarter in the previous year.
Its net income has increased by 624.6% to $23M since the same quarter in the previous year.
Finally, its free cash flow grew by 497.3% to $16M since the same quarter in the previous year.
Based on the above factors, XOMA Corporation gets an overall score of 5/5.